Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Therapy of Thymoglobulin Versus Basiliximab in the Prevention of Acute Rejection After Pediatric Kidney Transplantation

NCT06087003 is registered in ClinicalTrials.gov with Gang Chen as lead sponsor.

NCT NCT06087003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06087003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Therapy of Thymoglobulin Versus Basiliximab in the Prevention of Acute Rejection After Pediatric Kidney Transplantation
Lead sponsor
Gang Chen
Phase
Observational
Overall status
Completed
Start date
March 3, 2013
Completion date
September 30, 2023
Enrollment
958 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection, pediatric kidney disease